Analyst Reco. Vor Biopharma Inc.

Equities

VOR

US9290331084

Delayed Nasdaq Other stock markets 12:39:19 28/06/2024 am IST			5-day change	1st Jan Change
1.15 ^USD	0.00%		-5.00%	-49.33%

13/06	Voyager Therapeutics Names Nathan Jorgensen as Finance Chief	MT
10/06	Vor Biopharma Inc. Announces Management Appointments, Effective June 21, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Adjusts Vor Biopharma Price Target to $10 From $15, Maintains Outperform Rating	13/05	MT
Stifel Cuts Price Target on Vor Biopharma to $12 From $15, Maintains Buy Rating	21/03	MT
Oppenheimer Cuts Vor Biopharma Price Target to $15 From $18, Maintains Outperform Rating	21/03	MT
Wedbush Cuts Vor Biopharma's Price Target to $11 From $18, Keeps Outperform Rating	11/23/11	MT
JonesTrading Starts Vor Biopharma at Buy With $18 Price Target	16/23/16	MT
Barclays Adjusts Price Target on Vor Biopharma to $10 From $15, Maintains Overweight Rating	24/23/24	MT
HC Wainwright Adjusts Price Target on Vor Biopharma to $17.50 From $20, Maintains Buy Rating	24/23/24	MT
Stifel Adjusts Price Target on Vor Biopharma to $16 From $17, Maintains Buy Rating	24/23/24	MT
Baird Adjusts Vor Biopharma Price Target to $22 From $38, Maintains Outperform Rating	24/23/24	MT
JMP Securities Adjusts Price Target on Vor Biopharma to $12 From $15, Maintains Market Outperform Rating	19/23/19	MT
Oppenheimer Adjusts Vor Biopharma Price Target to $18 From $27, Maintains Outperform Rating	14/22/14	MT
Stifel Nicolaus Adjusts Vor Biopharma Price Target to $17 From $21, Maintains Buy Rating	11/22/11	MT
Barclays Adjusts Price Target on Vor Biopharma to $15 From $26, Maintains Overweight Rating	11/22/11	MT
HC Wainwright Adjusts Vor Biopharma's Price Target to $20 From $26, Keeps Buy Rating	15/22/15	MT
Stifel Adjusts Vor Biopharma's Price Target to $21 from $24, Keeps Buy Rating	12/22/12	MT
Wedbush Starts Vor Biopharma at Outperform With $18 Price Target	26/22/26	MT
Goldman Sachs Adjusts Price Target for Vor Biopharma to $4 From $6, Reiterates Neutral Rating	24/22/24	MT
JMP Securities Adjusts Vor Biopharma's Price Target to $15 From $30, Maintains Market Outperform Rating	13/22/13	MT
Goldman Sachs Starts Vor Biopharma at Neutral With $6 Price Target	27/22/27	MT
Barclays Adjusts Vor Biopharma's Price Target to $26 From $56; Overweight Rating Kept	21/22/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Vor Biopharma Inc.

Equities

VOR

US9290331084

Analyst Reco.

Filters